Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49.

Article  Google Scholar 

Li H, Zhang H, Zhang H, Wang Y, Wang X, Hou H. Survival of gastric cancer in China from 2000 to 2022: a nationwide systematic review of hospital-based studies. J Global Health. 2022;12.

Pihlak R, Fong C, Starling N. Targeted therapies and developing Precision Medicine in Gastric Cancer. Cancers. 2023;15.

Pous A, Notario L, Hierro C, Layos L, Buges C. HER2-Positive gastric Cancer: the role of Immunotherapy and Novel therapeutic strategies. Int J Mol Sci. 2023;24.

Romond EHP, Edith A, Bryant J, Suman VJ, Geyer CE, Davidson, Nancy E, Tan-Chiu E, Martino S, Paik S. Kaufman, Peter A: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med. 2005;353:1673–84.

Article  PubMed  CAS  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167–92.

Article  PubMed  CAS  Google Scholar 

Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53:1186–95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim CG, Jung M, Kim HS, Lee CK, Jeung HC, Koo DH, Bae WK, Zang DY, Kim BJ, Kim H, et al. Trastuzumab Combined with Ramucirumab and Paclitaxel in patients with previously treated human epidermal growth factor receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer. J Clin Oncol. 2023;41:4394–405.

Article  PubMed  CAS  Google Scholar 

Zheng X, Wang R, Zhang X, Sun Y, Zhang H, Zhao Z, Zheng Y, Luo J, Zhang J, Wu H et al. A deep learning model and human-machine fusion for prediction of EBV-associated gastric cancer from histopathology. Nat Commun. 2022;13.

Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, Marx A, Boor P, Tacke F, Neumann UP, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25:1054–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shah MAK, Erin B, Alarcon-Rozas AE. Rajdev, Lakshmi: Immunotherapy and targeted Therapy forAdvanced Gastroesophageal Cancer:ASCO Guideline. J Clin Oncol. 2023;41:1470–91.

Article  PubMed  CAS  Google Scholar 

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article  PubMed  CAS  Google Scholar 

Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.

Article  PubMed  PubMed Central  Google Scholar 

Luo Y, Chen J, Huang K, Lin Y, Chen M, Xu L, Li ZP, Feng ST. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC Cancer. 2017;17:154.

Article  PubMed  PubMed Central  Google Scholar 

Qiu ML, Guan M, Sun W-L. Yu-Ting;: Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systematic therapy of gastric cancer. J Clin Oncol. 2022 Jun 1;40:e16063.

Lan J, Cai S, Xue Y, Gao Q, Du M, Zhang H, Wu Z, Deng Y, Huang Y, Tong T, Chen G. Unpaired stain style transfer using Invertible neural networks based on Channel attention and long-range residual. IEEE Access. 2021;9:11282–95.

Article  Google Scholar 

Zhang Y, Deng Y, Zou Q, Jing B, Cai P, Tian X, Yang Y, Li B, Liu F, Li Z, et al. Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging. Cell Rep Med. 2024;5:e16063–16063.

Google Scholar 

Schrammen PL, Ghaffari Laleh N, Echle A, Truhn D, Schulz V, Brinker TJ, Brenner H, Chang-Claude J, Alwers E, Brobeil A, et al. Weakly supervised annotation‐free cancer detection and prediction of genotype in routine histopathology. J Pathol. 2021;256:50–60.

Article  PubMed  Google Scholar 

Vuong TTL, Song B, Kwak JT, Kim K. Prediction of Epstein-Barr Virus Status in gastric Cancer biopsy specimens using a deep learning algorithm. JAMA Netw Open. 2022;5:e2236408–18.

Article  PubMed  PubMed Central  Google Scholar 

Cao R, Yang F, Ma S-C, Liu L, Zhao Y, Li Y, Wu D-H, Wang T, Lu W-J, Cai W-J, et al. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Theranostics. 2020;10:11080–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases. 2019;7:1964–77.

Article  PubMed  PubMed Central  Google Scholar 

Tanei T, Seno S, Sota Y, Hatano T, Kitahara Y, Abe K, Masunaga N, Tsukabe M, Yoshinami T, Miyake T et al. High HER2 Intratumoral heterogeneity is a predictive factor for poor prognosis in early-stage and locally Advanced HER2-Positive breast Cancer. Cancers (Basel). 2024;16.

Bychkov D, Linder N, Tiulpin A, Kücükel H, Lundin M, Nordling S, Sihto H, Isola J, Lehtimäki T, Kellokumpu-Lehtinen P-L, et al. Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy. Sci Rep. 2021;11:4037–46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Farahmand S, Fernandez AI, Ahmed FS, Rimm DL, Chuang JH, Reisenbichler E, Zarringhalam K. Deep learning trained on hematoxylin and eosin tumor region of interest predicts HER2 status and trastuzumab treatment response in HER2 + breast cancer. Mod Pathol. 2022;35:44–51.

Article  PubMed  CAS  Google Scholar 

Ha GY, Yang SH, Kang HJ, Lee HL, Kim J, Kim YJ, Yu HJ, Lee JI, Jin SH. Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy. Korean J Clin Oncol. 2020;16:63–70.

Article  PubMed  PubMed Central  Google Scholar